Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases

系统性自身免疫性风湿病患者 COVID-19 后的免疫学和临床后遗症

• 批准号: 10583192
• 负责人: Jeffrey Andrew Sparks
• 金额: $ 78.25万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-02-01 至 2028-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10583192
• 关键词: 2019-nCoV; Acute; Affect; American; Antibodies; Antibody Response; Autoantibodies; Autoimmunity; B-Lymphocytes; Biophysics; COVID-19; COVID-19 impact; COVID-19 pandemic; COVID-19 pathogenesis; COVID-19 risk; COVID-19 survivors; Characteristics; Chest; Chest imaging; Clinical; Community Hospitals; Complication; Coronavirus; Data; Diagnostic; Disease; Disease Outbreaks; Dose; Effectiveness; Etiology; Evolution; Fibrosis; General Hospitals; General Population; High Resolution Computed Tomography; Hospitals; Humoral Immunities; Image; Immune; Immune response; Immunologics; Immunomodulators; Immunosuppressive Agents; Infection; Knowledge; Lead; Massachusetts; Measures; Medicine; National Institute of Arthritis, and Musculoskeletal, and Skin Diseases; Observational Study; Outcome; Patients; Phenotype; Post-Acute Sequelae of SARS-CoV-2 Infection; Predisposition; Principal Investigator; Prospective cohort; Pulmonary Fibrosis; RNA vaccine; Recommendation; Research; Respiratory Signs and Symptoms; Retrospective cohort study; Rheumatoid Arthritis; Risk; SARS-CoV-2 infection; Sampling; Source; Symptoms; System; Systemic Lupus Erythematosus; TNF gene; Vaccinated; Vaccination; Vaccines; Variant; Viral; Virus Diseases; Virus Shedding; Vulnerable Populations; Woman; Work; autoimmune rheumatologic disease; breakthrough infection; cohort; coronavirus disease; fibrotic lung disease; high risk; inhibitor; medical schools; pandemic disease; participant enrollment; pathogen; post-COVID-19; professor; prospective; prototype; public health relevance; respiratory; response; rheumatologist; rituximab; tertiary care; therapy resistant; vaccine immunogenicity; virology

PROJECT SUMMARY The 5 million Americans living with systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), are at increased risk of poor COVID-19 outcomes. SARO treatment with immunomodulators may lead to blunted and dysregulated immune responses to vaccination and infection. SARDs are characterized by a predisposition to autoantibody formation and fibrosis. These factors may place SARDs at risk for poor short-term outcomes (e.g., breakthrough infection, prolonged viral shedding) and post-acute sequelae of COVID-19 (PASC), characterized by prolonged COVID-19 symptoms (>/=28 days). PASC is of high clinical and

项目总结